Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/55665
SERUM BIOMARKERS ASSOCIATED WITH SARS-COV-2 SEVERITY
Author
Batista, Fabiani de Morais
Puga, Marco Antonio Moreira
Silva, Patricia Vieira da
Oliveira, Roberto
Santos, Paulo Cesar Pereira dos
Silva, Bruna Oliveira da
Tatara, Mariana Bento
Tsuha, Daniel Henrique
Pires, Maria Aparecida dos Santos
Gonçalves, Crhistinne Cavalheiro Maymone
Silva, Rômulo Pessoa E.
Ferreira, Nathália Tavares
Albuquerque, Amanda Pinheiro de Barros
Duarte, Giselle da Silva
Consolaro, Márcia Edilaine Lopes
Negrão, Fabio Juliano
Ferrari, Idalina Cristina
Cavalcanti, Luciano Pamplona de Goes
Trinta, Karen Soares
Ribeiro, Guilherme S.
Rêgo, Moacyr Jesus Barreto de Melo
Boyton, Rosemary J.
Siqueira, André Machado
Altmann, Daniel M.
Croda, Julio
Puga, Marco Antonio Moreira
Silva, Patricia Vieira da
Oliveira, Roberto
Santos, Paulo Cesar Pereira dos
Silva, Bruna Oliveira da
Tatara, Mariana Bento
Tsuha, Daniel Henrique
Pires, Maria Aparecida dos Santos
Gonçalves, Crhistinne Cavalheiro Maymone
Silva, Rômulo Pessoa E.
Ferreira, Nathália Tavares
Albuquerque, Amanda Pinheiro de Barros
Duarte, Giselle da Silva
Consolaro, Márcia Edilaine Lopes
Negrão, Fabio Juliano
Ferrari, Idalina Cristina
Cavalcanti, Luciano Pamplona de Goes
Trinta, Karen Soares
Ribeiro, Guilherme S.
Rêgo, Moacyr Jesus Barreto de Melo
Boyton, Rosemary J.
Siqueira, André Machado
Altmann, Daniel M.
Croda, Julio
Affilliation
Federal University of Mato Grosso do Sul. School of Medicine. Campo Grande, MS, Brazil.
Federal University of Mato Grosso do Sul. School of Medicine. Campo Grande, MS, Brazil.
Federal University of Mato Grosso do Sul. School of Medicine. Campo Grande, MS, Brazil.
State University of Mato Grosso do Sul. Associated Prof. Nursing Course. Dourados, MS, Brazil.
Federal University of Mato Grosso do Sul. School of Medicine. Campo Grande, MS, Brazil.
Federal University of Grande Dourados. Faculty of Health Science. Laboratory of Research in Health Science. Dourados, MS, Brazil.
Federal University of Grande Dourados. Faculty of Health Science. Laboratory of Research in Health Science. Dourados, MS, Brazil.
Center for Strategic Information in Health Surveillance. State Health Department of Mato Grosso do Sul. Campo Grande, MS, Brazil.
Federal University of Grande Dourados. Faculty of Health Sciences. Dourados, MS, Brazil / Federal University of Grande Dourados. Universitary Hospital. Dourados, MS, Brazil.
Federal University of Mato Grosso do Sul. School of Medicine. Campo Grande, MS, Brazil.
Federal University of Pernambuco. Recife, PE, Brazil.
Federal University of Pernambuco. Recife, PE, Brazil.
Federal University of Pernambuco. Recife, PE, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica de Doença Febril Aguda. Rio de Janeiro, RJ, Brasil.
State University of Maringá. Postgraduate Program in Biosciences and Pathophysiology. Maringá, PR, Brazil / State University of Maringá. Regional University Hospital of Maringá. Maringá, PR, Brazil.
Federal University of Grande Dourados. Faculty of Health Sciences. Dourados, MS, Brazil / Federal University of Grande Dourados. Universitary Hospital. Dourados, MS, Brazil.
Federal University of Grande Dourados. Faculty of Health Sciences. Dourados, MS, Brazil.
Federal University of Ceará. Postgraduate Program in Public Health. Fortaleza, CE, Brazil / Christus University Center. School of Medicine. Fortaleza, CE, Brazil / Federal University of Ceará. Postgraduate Program in Pathology. Fortaleza, CE, Brazil .
Fundação Oswaldo Cruz. Bio-manguinhos. Laboratório de Tecnologia Diagnóstica. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil.
Federal University of Pernambuco. Recife, PE, Brazil.
Imperial College London. Department of Infectious Disease. London, UK / Royal Brompton. Lung Division. London, UK / Harefield Hospitals. London, UK.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Imperial College London. Department of Immunology and Inflammation. London, UK.
Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, MS, Brasil / Federal University of Mato Grosso do Sul. School of Medicine. Campo Grande, MS, Brazil.
Federal University of Mato Grosso do Sul. School of Medicine. Campo Grande, MS, Brazil.
Federal University of Mato Grosso do Sul. School of Medicine. Campo Grande, MS, Brazil.
State University of Mato Grosso do Sul. Associated Prof. Nursing Course. Dourados, MS, Brazil.
Federal University of Mato Grosso do Sul. School of Medicine. Campo Grande, MS, Brazil.
Federal University of Grande Dourados. Faculty of Health Science. Laboratory of Research in Health Science. Dourados, MS, Brazil.
Federal University of Grande Dourados. Faculty of Health Science. Laboratory of Research in Health Science. Dourados, MS, Brazil.
Center for Strategic Information in Health Surveillance. State Health Department of Mato Grosso do Sul. Campo Grande, MS, Brazil.
Federal University of Grande Dourados. Faculty of Health Sciences. Dourados, MS, Brazil / Federal University of Grande Dourados. Universitary Hospital. Dourados, MS, Brazil.
Federal University of Mato Grosso do Sul. School of Medicine. Campo Grande, MS, Brazil.
Federal University of Pernambuco. Recife, PE, Brazil.
Federal University of Pernambuco. Recife, PE, Brazil.
Federal University of Pernambuco. Recife, PE, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica de Doença Febril Aguda. Rio de Janeiro, RJ, Brasil.
State University of Maringá. Postgraduate Program in Biosciences and Pathophysiology. Maringá, PR, Brazil / State University of Maringá. Regional University Hospital of Maringá. Maringá, PR, Brazil.
Federal University of Grande Dourados. Faculty of Health Sciences. Dourados, MS, Brazil / Federal University of Grande Dourados. Universitary Hospital. Dourados, MS, Brazil.
Federal University of Grande Dourados. Faculty of Health Sciences. Dourados, MS, Brazil.
Federal University of Ceará. Postgraduate Program in Public Health. Fortaleza, CE, Brazil / Christus University Center. School of Medicine. Fortaleza, CE, Brazil / Federal University of Ceará. Postgraduate Program in Pathology. Fortaleza, CE, Brazil .
Fundação Oswaldo Cruz. Bio-manguinhos. Laboratório de Tecnologia Diagnóstica. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil.
Federal University of Pernambuco. Recife, PE, Brazil.
Imperial College London. Department of Infectious Disease. London, UK / Royal Brompton. Lung Division. London, UK / Harefield Hospitals. London, UK.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Imperial College London. Department of Immunology and Inflammation. London, UK.
Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, MS, Brasil / Federal University of Mato Grosso do Sul. School of Medicine. Campo Grande, MS, Brazil.
Abstract
Immunity with SARS-CoV-2 infection during the acute phase is not sufficiently well understood to differentiate mild from severe cases and identify prognostic markers. We evaluated the immune response profile using a total of 71 biomarkers in sera from patients with SARS-CoV-2 infection, confirmed by RT-PCR and controls. We correlated biological marker levels with negative control (C) asymptomatic (A), nonhospitalized (mild cases-M), and hospitalized (severe cases-S) groups. Among angiogenesis markers, we identified biomarkers that were more frequently elevated in severe cases when compared to the other groups (C, A, and M). Among cardiovascular diseases, there were biomarkers with differences between the groups, with D-dimer, GDF-15, and sICAM-1 higher in the S group. The levels of the biomarkers Myoglobin and P-Selectin were lower among patients in group M compared to those in groups S and A. Important differences in cytokines and chemokines according to the clinical course were identified. Severe cases presented altered levels when compared to group C. This study helps to characterize biological markers related to angiogenesis, growth factors, heart disease, and cytokine/chemokine production in individuals infected with SARS-CoV-2, offering prognostic signatures and a basis for understanding the biological factors in disease severity.
Share